Centogene (CNTGF) AI Stock Analysis

• Market Cap: $3.28M
• Dividend Yield: N/A
• Average Volume (3M): 1.26K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 493
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical Diagnostics & Screening
• EPS (TTM): N/A
• Shares Outstanding: 29,817,080
• 10 Day Avg. Volume: 717
• 30 Day Avg. Volume: 1,260
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

No summary available

Positive Factors

Business Model Strength

Centogene's business model leverages its expertise in rare disease diagnostics and genetic testing, providing stable revenue streams through long-term contracts and collaborative research agreements with pharmaceutical companies.

Strategic Partnerships

Strategic partnerships with pharmaceutical companies enhance Centogene's market position, offering growth opportunities through drug development support and biomarker discovery, which are crucial for long-term success in the biotech sector.

Data Monetization Potential

The company's genetic database offers significant monetization potential through licensing and data-driven projects, providing a competitive edge and additional revenue streams in the evolving field of precision medicine.

Negative Factors

High Leverage

High leverage poses a risk to Centogene's financial health, limiting its ability to invest in growth opportunities and increasing vulnerability to economic downturns, which could impact long-term sustainability.

Negative Cash Flow

Persistent negative cash flow reflects operational inefficiencies and reliance on external financing, which could hinder Centogene's ability to fund future growth and maintain financial stability over time.

Stagnant Revenue Growth

Stagnant revenue growth highlights challenges in expanding market share and increasing sales, which could impede Centogene's ability to achieve profitability and sustain its competitive position in the long term.

Centogene Business Overview & Revenue Model

Company Description

Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

How the Company Makes Money

Centogene generates revenue primarily through its diagnostic services and collaborations with pharmaceutical companies. The company offers a wide range of genetic testing services, including whole exome and genome sequencing, which are utilized by healthcare providers to diagnose rare hereditary diseases. Additionally, Centogene partners with pharmaceutical companies to support drug development and clinical trials by providing biomarker discovery and patient stratification services. These partnerships often involve long-term contracts and collaborative research agreements, contributing significantly to the company's earnings. Centogene's extensive database of genetic information also provides a valuable resource for research and development, enabling further monetization opportunities through licensing and data-driven projects.

Centogene Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	17.25M	19.76M	28.16M	44.94M	22.77M
EBITDA	-20.48M	-55.30M	-24.73M	-4.93M	-12.09M
Net Income	-35.53M	-63.83M	-92.62M	-21.38M	-20.86M
Balance Sheet
Total Assets	77.16M	92.81M	90.69M	150.13M	117.51M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	80.73M	60.12M	22.81M	24.10M	26.97M
Total Liabilities	102.44M	88.71M	65.90M	84.35M	58.59M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-33.94M	4.00M	-27.23M	-8.09M	-15.35M
Operating Cash Flow	-31.75M	5.23M	-21.70M	8.46M	-7.78M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Centogene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.11
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTGF, the sentiment is Negative. The current price of 0.11 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.11, and above the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTGF.

Centogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNTGF	―	$3.28M	―	140.54%	―	―	―
UPC	46 Neutral	$1.31M	>-0.01	2.66%	―	-27.81%	―
AEMD	45 Neutral	$3.02M	-0.28	-191.39%	―	―	76.53%
AZTR	43 Neutral	$4.81M	-0.12	-215.04%	―	-100.00%	93.82%
ENVB	42 Neutral	$2.78M	-0.32	-262.78%	―	―	79.45%
REVB	42 Neutral	$4.54M	-2.23	-0.40%	―	―	96.26%